key: cord-0924001-gf32b71y
authors: Sánchez-Martínez, Francesca; Arenas-Miras, Mar; Jové-Caballé, Neus; Knobel-Freud, H
title: Influence of cytokine release syndrome in severe COVID-19 patients treated with tocilizumab over the Quantiferon TB Gold Plus results
date: 2021-02-13
journal: Arch Bronconeumol
DOI: 10.1016/j.arbres.2021.02.003
sha: 80a0688ebfa2583563f40bf7d9e456b3ee0ec47b
doc_id: 924001
cord_uid: gf32b71y

nan

J o u r n a l P r e -p r o o f CARTA CIENTÍFICA Influence of cytokine release syndrome in severe COVID-19 patients treated with tocilizumab over the Quantiferon TB Gold Plus results. Influencia de la tormenta citoquímica de pacientes COVID-19 graves tratados con tocilizumab sobre los resultados del Quantiferon TB Gold Plus.

Authors: Francesca Sánchez-Martínez (1), Mar Arenas-Miras (1), Neus Jové-Caballé (1) (Table 1 ).

These data illustrate that SARS CoV-2, while producing an exacerbated inflammatory response, may be associated with T-lymphocyte depletion-dysfunction, which may reduce the capability of Quantiferon TB Gold Plus to identify the LTBI response in patients with moderate and severe COVID-19. In our cohort, severe COVID-19 patients with cytokine release syndrome, showed medians of CD4+ and CD8+ below 350 and 200 cells/mL, respectively, which were probably the cause of the higher-than-expected indeterminate QFN values (40.3%). Similar results have been seen in several IGRA-based LTBI studies in immunosuppressed individuals , (10, 11) .

Since SARS CoV-2 could influence the dynamics of M. tuberculosis, specific follow-up of recovered COVID-19 patients at high risk factors of developing active TB should be considered independently of the results of QFN.

Effective treatment of severe COVID-19 patients with tocilizumab

Tocilizumab for severe COVID-19: a systematic review and metaanalysis

Understanding SARS-CoV-2-Mediated Inflammatory Responses: From Mechanisms to Potential Therapeutic Tools

Endothelial cell dysfunction: a major player SARS-CoV-2 infection (COVID-19)?

Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors

Coronavirus activates a stem cell-mediated defense mechanism that reactivates dormant tuberculosis: implications in COVID-19 pandemic

Coinfection of Tuberculosis Pneumonia and COVID-19 in a Patient Vaccinated with Bacille Calmette-Guérin (BCG): Case Report

Guidelines for the use of interferon-γ release assays in the diagnosis of tuberculosis infection

The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement

Gamma interferon release assays for detection of Mycobacterium tuberculosis infection